Table 1 Baseline characteristics of Ad5/3-cox2L-D24-treated patients
ID | Age sex | Cox2x statusa | Diagnosis b | Prior therapies | WHO (ECOG) c |
|---|---|---|---|---|---|
K2 | 48 M | +++ | NSCLC | Radiation therapy to vertebral column and sternum, followed by cisplatin+docetaxel × 3 and pemetrexed × 5. Erlotinib for ca 6 months. Recently, radiation to pelvic girdle and head | 1 |
S4 | 50 M | + | MFH | Operated. Adjuvant doxorubicin+ifosfamide × 6. Lung metastases operated. Doxorubicin+ifosfamide repeated. Radiation therapy | 4 |
H5 | 60 M | NA | Pancreatic cancer | Gemcitabine+capecitabine, chemoradiotherapy with gemcitabine, gemcitabine+ erlotinib, capecitabine+oxaliplatin | 2 |
C6 | 46 M | — | Sigmoid colon cancer | Operated. Adjuvant capecitabine × 6. Later treated with capecitabine+irinotecan, capecitabine+bevacizumab, 5-fluorouracil+leucovorin+oxaliplatin, irinotecan+gemcitabine+bevacizumab | 1 |
H7 | 61 F | +++ | Pancreatic cancer | Operated. Adjuvant gemcitabine for 6 months. Capecitabine+oxaliplatin | 1 |
O9 | 61 F | ++ | Serous ovarian adeno-carcinoma | Operated. Paclitaxel+carboplatin, gemcitabine+carboplatin, single-agent gemcitabine, liposomal doxorubicin, topotecan | 1 |
R10 | 43 F | + | Breast cancer, BRCA1+ ER- PR-Her2- | Operated: hysterectomy, s-o-ectomy, and mastectomy. Adjuvant cyclophosphamide+ epirubicin+5-fluorouracil × 3, docetaxel × 3. Later capecitabine+docetaxel, cyclophosphamide+epirubicin+5-fluorouracil × 8, epirubicin × 11, carboplatin+ gemcitabine × 8, vinorelbine+methotrexate+5-fluorouracil × 4, cyclophosphamide+ liposomal doxorubicin. Recently, radiation to sternum and head | 3 |
G11 | 49 F | ++ | Gastric cancer | Operated. Chemoradiotherapy with 5-fluorouracil. Later capecitabine+oxaliplatin+ epirubicin, single-agent docetaxel, irinotecan+gemcitabine+erlotinib+bevacizumab, docetaxel+erlotinib+bevacizumab | 2 |
C13 | 62 F | +++ | Sigmoid colon cancer | Operated. Leucovorin+5-fluorouracil+irinotecan, capecitabine+oxaliplatin, capecitabine+bevacizumab, etuximab+leucovorin+5-fluorouracil+irinotecan, and capecitabine+bevacizumab | 1 |
O16 | 62 F | ++ | Fallopian tube cancer | Operated. Paclitaxel+carboplatin, single-agent gemcitabine, liposomal doxorubicin, topotecan, docetaxel, single-agent paclitaxel, vinorelbine, etoposide, oxaliplatin+bevacizumab+erlotinib, single-agent erlotinib | 2 |
C17 | 56 M | +++ | Sigmoid colon cancer | Operated. 5-fluorouracil, 5-fluorouracil+leucovorin+oxaliplatin, gemcitabine+ irinotecan+carmofur (HCFU)+leucovorin, bevacizumab+erlotinib | 1 |
P20 | 74 M | +++ | Prostate cancer | Leuprorelin. Radiation therapy. Bicalutamide. Bicalutamide+leuprorelin. Flutamide. Radiation therapy. Docetaxel+zoledronic acid, docetaxel+zoledronic acid +estramustine, zoledronic acid+epirubicin | 2 |
N21 | 5 M | + | Neuroblastoma | Vincristine+cisplatin+etoposide+cyclophosphamide alternated with vincristine+carboplatin+etoposide+cyclophosphamide. Doxorubicin+etoposide+ iphosphamide. Intensive chemotherapy and autologous stem cell transplant. Oral 13-cis-retinoic acid | 0 |
H22 | 62 F | +++ | Pancreatic cancer | Operated. Gemcitabine, chemoradiotherapy with gemcitabine | 2 |
O24 | 53 F | NA | Ovarian adeno-carcinoma | Operated, post-operative chemotherapy. Relapse 6 years ago, chemotherapy. Paclitaxel, paclitaxel+carboplatin, single-agent carboplatin, liposomal doxorubicin, topotecan, etoposide | 1 |
O25 | 48 F | NA | Ovarian adeno-carcinoma | Operated. Paclitaxel+carboplatin. Recurrence, debulking surgery, liposomal doxorubicin, topotecan, gemcitabine, treosulfan+bevacizumab, paclitaxel+bevacizumab | 2 |
P27 | 70 M | +++ | Prostate cancer | Neoadjuvant hormone therapy, radiation therapy. Leuprorelin, bicalutamide, leuprorelin again, docetaxel. Palliative radiation therapy. Estramustine, flutamide, bicalutamide again, zoledronic acid. | 2 |
O37 | 54 F | ++ | Serous ovarian adeno-carcinoma | Operated. Paclitaxel+carboplatin, gemcitabine+carboplatin, cisplatin+gemcitabine | 2 |
